Amgen (Thousand Oaks, CA) and Xencor, Inc. (Monrovia, CA) will collaborate to develop XmAb5871, an Fc-engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases.
Amgen (Thousand Oaks, CA) and Xencor, Inc. (Monrovia, CA) will collaborate to develop XmAb5871, an Fc-engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases.
Xencor's CD32b technology is an immunomodulatory platform consisting of engineered Fc domains with selective high affinity binding to FcyRIIb (CD32b), a receptor with dominant inhibitory activity on B cells and other immune cells. The CD32b pathway has never been therapeutically exploited and applied to high-affinity antibodies targeting immune cells.
Under the terms of the agreement, Amgen has the option to an exclusive worldwide license following the completion of a predefined Phase 2 study. Xencor will lead all clinical development until that time. Xencor will receive an upfront payment, and early development milestone payments. If Amgen does exercise its option, Amgen will assume responsibility for future development. Xencor will receive an option-exercise fee which, combined with the upfront and early development milestones, will total $75 million, and Xencor could receive up to an additional $425 million in clinical, regulatory, and commercialization milestone payments.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.